Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

HER2-Negative Breast Cancer: Global Drug Forecast and Market Analysis to 2028

Published by GlobalData Product code 929723
Published Content info 173 Pages
Delivery time: 1-2 business days
Price
Back to Top
HER2-Negative Breast Cancer: Global Drug Forecast and Market Analysis to 2028
Published: February 28, 2020 Content info: 173 Pages
Description

Human epidermal growth factor receptor type 2 (HER2)-negative breast cancer is one of the most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can generally be subdivided into two major groups: HER2-, estrogen receptor (ER)+ and/or progesterone receptor (PR)+ and HER2-, ER-, and PR- (triple-negative breast cancer, or TNBC). Historically HR+ breast cancer has typically been treated with hormone therapies which is the cornerstone of treatment for patients with this disease while physicians have typically relied on chemotherapy for patients with triple negative breast cancer. This has significantly changed in the last 5 years.

GlobalData is expecting a total of 9 new entrants to launch over the forecast period in the 8MM from 2018-2028 while specific marketed agents are expected to move into earlier lines of treatment. The competition will be particularly fierce in HER2-/HR+ breast cancer, with CDK4/6, PI3K/AKT, and HDAC inhibitors competing for market share with endocrine-based therapies in later lines of treatment. In TNBC, checkpoint inhibitors, PARP inhibitors and antibody drug conjugates will compete in specific patient segments, and are expected to ultimately lower the unmet needs in this patient population.

KEY QUESTIONS ANSWERED

  • Nine late-stage pipeline agents are going to enter the HER2-negative breast cancer market from 2018 onwards. Will the impact will these agents have on the market?
  • Which of these drugs will have the highest peak sales, and why?
  • What are the current unmet needs in HER2-negative breast cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
  • What is the market outlook in the 8MM from 2018-2028? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
  • What are the main corporate trends? Who are the current and future players?

Scope

  • Overview of HER2-negative breast cancer including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Topline HER2-negative breast cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
  • Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HER2-negative breast cancer therapeutics sales in the 8MM.
  • Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
  • Analysis of the current and future market competition in the global HER2-negative breast cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global HER2-negative breast cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-negative breast cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global HER2-negative breast cancer therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
Product Code: GDHC183PIDR

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 HER2-Negative Breast Cancer: Executive Summary

  • 2.1 The HER2-Negative Breast Cancer Market Will Expand to $13.04B in 2028
  • 2.2 A Focus on Establishing Greater Market Access, Label Expansions for Premium Products, and New Products in Later Lines
  • 2.3 Opportunities Remain for More Effective and Conveniently Administered Therapies in HER2-Negative Breast Cancer
  • 2.4 Checkpoint Inhibitors and PI3K/AKT Inhibitors Are Well Positioned for Significant Market Penetration Over the Forecast Period
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
    • 5.3.1 US
    • 5.3.2 5EU
    • 5.3.3 Japan
    • 5.3.4 China (Urban)
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Sources Not Used - 5EU
    • 5.4.3 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for HER2-Negative Breast Cancer (2018-2028)
    • 5.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer
    • 5.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer
    • 5.5.3 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer
    • 5.5.4 Diagnosed Incident Cases of TN Breast Cancer
    • 5.5.5 Proportion of Diagnosed Incident cases of HER2-/HR+ Breast Cancer by Stages
    • 5.5.6 Proportion of Diagnosed Incident cases of TN Breast Cancer by Stages
    • 5.5.7 Diagnosed Incident Cases of HER2-/HR+ Breast Cancer by Menopausal Status
    • 5.5.8 Diagnosed Incident cases of HER2-Negative Breast Cancer by PD-1 and PD-L1 Expression
    • 5.5.9 Diagnosed Incident Cases of HER2-Negative Breast Cancer with BRCA Mutation
    • 5.5.10 Diagnosed Incident Cases of HER2-Negative Breast Cancer with PI3KCA Mutation
    • 5.5.11 Diagnosed Incident Cases of HER2-Negative Breast Cancer by Bone Metastasis
    • 5.5.12 Diagnosed Incident Cases of HER2-Negative Breast Cancer with Brain/CNS Metastasis
    • 5.5.13 Five-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer
    • 5.5.14 Five-Year Diagnosed Prevalent Cases of HER2-Negative Breast cancer
    • 5.5.15 10-Year Diagnosed Prevalent Cases of All Invasive Breast Cancer
    • 5.5.16 10-Year Diagnosed Prevalent Cases of HER2-Negative Breast cancer
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of Analysis
    • 5.6.3 Strengths of Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan
  • 6.5 China

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Developing More Personalized Treatment Options for TNBC Patients
  • 8.3 Developing Novel Strategies to Tackle Endocrine Resistance in HR+ Disease
  • 8.4 Improved Convenience for Administration of Hormonal Agents
  • 8.5 Effective Treatment Strategies for Patients with Brain Metastases

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 Pfizer
  • 10.4 Novartis
  • 10.5 Eli Lilly
  • 10.6 AstraZeneca
  • 10.7 Roche
  • 10.8 Merck & Co
  • 10.9 Other Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: HER2-Negative Breast Cancer Key Metrics in the 8MM
  • Table 2 : Inherited Gene Mutations Associated With Lifetime Breast Cancer Risk
  • Table 3: Established and Probable Risk Factors Associated With Breast Cancer Development
  • Table 4: Mol

List of Figures

  • Figure 1: Global Sales Forecast by Country for HER2-Negative Breast Cancer in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in HER2-Negative Breast Cancer During the Forecast Period
  • Figure 3: Competitive Assessment of the L
Back to Top